AG-24322

N/A

Report date: 2026/01/06 18:01:02
NME

Base Information

Drug NameAG-24322
Drug Alias NameAG-24322AG-024322
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 1 inhibitorsCyclin-dependent kinase 2 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 1Cyclin-dependent kinase 2Cyclin-dependent kinase 4
Therapy Area/IndicationsLymphoma, Non-HodgkinNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-HodgkinNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A